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Abstract
Background: Platelet rich plasma (PRP) is widely used in rotator cuff repairs but its effect on the healing process is
unclear. Several cell culture studies on the effect of allogenic PRP have reported promising results but are not
transferable to clinical practice.
The aim of the present study is to assess the possible effect of autologous PRP on rotator cuff tendon cells. The
amount of growth factors involved with tendon-bone healing (PDGF-AB, IGF-1, TGF-β1, BMP-7 and -12) is quantified.
Methods: Rotator cuff tissue samples were obtained from (n = 24) patients grouped by age (>/< 65 years) and sex into
four groups and cells were isolated and characterized. Later, autologous PRP preparations were obtained and the effect
was analyzed by means of cell proliferation, collagen I synthesis and expression of collagen I and III. Furthermore, the
PRPs were quantified for growth factor content by means of platelet-derived growth factor (PDGF-AB), insulin-like
growth factor (IGF-1), transforming growth factor (TGF-β1), as well as bone morphogenetic protein (BMP) -7 and − 12.
Results: Cell proliferation and absolute synthesis of collagen I were positively affected by PRP exposure
compared to controls (p < 0.05), but expression and relative synthesis of collagen I (normalized to cell
proliferation) were significantly reduced.
PRP contained high amounts of IGF-1 and lower levels of TGF-β1 and PDGF-AB. The amounts of BMP-7 and -12 were
below the detection limits.
Conclusions: PRP is a source of growth factors such involved with tendon-bone healing. PRP had an anabolic
effect on the human rotator cuff tenocytes of the same individual in vitro by means of cell proliferation and
absolute, but not relative collagen I synthesis.
These results encourage further studies on clinical outcomes with more comparable standards in terms of
preparation and application methods.
Level of evidence: Controlled laboratory study.
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Background
The ongoing development of new rotator cuff (RC) re-
pair techniques, such as double row repairs, has led to
increased initial biomechanical stability, but recent
meta-analyses have revealed that there is no clear clin-
ical and radiographic advantage in terms of improved
tendon integration [9, 15, 39, 42, 43, 48, 50]. As
non-healing still represents the main challenge follow-
ing surgical rotator cuff repair, biological approaches
have been suggested as a way to improve tendon-bone
healing [20, 23, 29, 36]. The use of growth factors
seems to improve biological regeneration, but many of
these are recombinant in origin and are often cost in-
tensive to acquire [31].
Platelet rich plasma (PRP) as a supraphysiological con-
centration of platelets is an easily producible, low-cost
source of several autologous growth factors [33].
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However, available studies on the effect of PRP on clin-
ical and radiographic parameters following RC repair do
not just differ in their preparation and application
methods, but also in their results. Recent meta-analyses
have described either no clinical benefit or no consistent
effect on re-tear rates, or at least uncertainty about the
evidence [5, 7, 30, 47, 51, 58, 60].
In-vitro studies on the effect of PRP have, however,
described improved tendon matrix production and gene
expression, but only PRP preparations that are allogenic
in origin were applied to tenocyte cultures, mainly with
no dedicated characterization, and these were primarily
obtained from monadic numbers of donors [12, 13, 17,
22, 24, 46]. In contrast, the process of assessing tendon
cell cultures with autologous PRP from the same pa-
tient matches with the clinical application, but has not
been described in the literature. This approach requires
a protocol to first harvest and culture cells, followed by
subsequent PRP production and application. Tendon
cell characterization should also be part of the ap-
proach to verify the targeted cell type.
The presence of several growth factors involved with
musculoskeletal repair, such as platelet-derived growth
factor (PDGF), transforming growth factor-β (TGF-β),
insulin-like growth factor (IGF), epidermal growth fac-
tor (EGF), vascular endothelial growth factor (VEGF),
and fibroblast growth factor (FGF), has been described
within PRP preparations [25, 33, 36, 52]. A focus on
tenocyte metabolism and improved tendon-bone heal-
ing has highlighted further growth factors, such as bone
morphogenetic protein 7 (BMP-7) [26, 27, 40, 56, 62]
and 12 (BMP-12) [29, 49, 59]. However, it is currently
unknown whether these are present in PRP.
The present study aims to characterize a human
PRP-preparation in terms of the quantity of various
growth factors. In addition, it investigates the effect of
autologous PRP on tenocyte-like cells for the first time.
We hypothesize that there will be improved cell pro-
liferation and collagen I synthesis under stimulation
with PRP.
Methods
Study design, inclusion and exclusion criteria
After receiving institutional review board approval,
supraspinatus (SSP) tendon samples were taken intraop-
eratively from n = 24 patients undergoing arthroscopic
RC repair. Participation in the study did not affect the
intra- and postoperative treatment strategy.
(N = 12) male and (n = 12) female patients with full
thickness tears of the SSP tendon were included in the
study. The exclusion criteria were partial- or massive
tears (larger than Bateman III° [2]), tears with fatty infil-
tration greater than Goutallier III° [18], and medical
conditions precluding arthroscopic cuff repair.
Donor demographics, tendon material, surgery (t = 0)
N = 12 female (Ø age 64.5 years; range 50–74 years)
and n = 12 male patients (Ø age 62.4 years; range, 38–
73 years) were included in the study and subdivided
into four groups by age (>/< 65 years) and sex. The
average age of all the patients at the time of surgery
was 63.5 years.
Cell isolation and culture
During arthroscopic RC repair and after debridement
with a shaver, all tendon biopsies were obtained 3-5
mm from the torn proximal tendon edge. Human
tenocyte-like cells (hTLCs) were isolated from these
SSP tendon biopsies by digestion with 0.3% collagenase
type CLS II in PBS with Ca2+/Mg2+ for 2 h at 37 °C, as
described previously [41]. The cells were cultured with
a normal growth medium (DMEM/Ham’s F12 with 10%
fetal calf serum (FCS), and 1% Penicillin/Streptomycin,
all Biochrom AG, Berlin, Germany) at 37 °C, with 95%
humidity and 5% carbon dioxide, and with a change of
medium every 2 to 3 days. The cells were cryo-pre-
served until they were used for the stimulation when
they reached a minimum of 5 × 105 vital cells.
Exemplary hTLC characterization
A total of 8 of the 24 hTLC cultures were characterized
according to previously published research [41]. The
cells were analyzed for their expression of the tendon
markers collagen I, scleraxis, and Mohawk homeobox,
and the negative markers collagen II and osteocalcin.
The relative gene expression levels were normalized to
glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
and calculated using the 2-ΔCt method.
PRP preparation
Approximately 2.5 years after their surgery, the 12 male
and 12 female SSP tendon patients were invited to do-
nate blood for the PRP preparation. The fresh PRP was
then used for the autologous stimulation of the hTLCs,
which had previously been isolated from their torn SSP
biopsies and stored until used for stimulation experi-
ments. A commercially available kit was used for the
standardized PRP preparation according to the manufac-
turer’s instructions: Arthrex ACP® (Arthrex, Naples, FL),
using 15 mL Arthrex ACP® double syringes. An average
of 5 mL of PRP was obtained from each of them. No
additional anticoagulants were used. Hence, quick prep-
aration and processing of the PRP were mandatory.
Directly after preparation, the PRP was analyzed for
the platelet count using a haemocytometer (C-Chip,
NanoEnTek, Seoul, Korea). After preparation, the
PRP was used to stimulate the hTLCs, and was then
subsequently cryo-preserved at − 20 °C until the
growth factor quantification.
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PRP-stimulation
A total of 1 × 104 vital cells per well were seeded in a
24-well plate in triplicate and cultured in a normal
growth medium. One day after seeding, an alamarBlue
assay (Biozym, Germany) was used to analyze the cell
proliferation. The cells then received either a growth
medium with 2% FCS (negative control), a growth
medium with 10% FCS (positive control), or 10% PRP in
a growth medium with 2% FCS. Six wells were used to
obtain enough RNA for the negative control. The PRP
was applied to the cells in a polycarbonate cell culture
insert with a pore size of 0.4 μm (Nunc), which was
placed on the cell layer. The experimental set up is
shown in Fig. 1. After incubating the cells for 5 days at
37 °C, the cell proliferation was analyzed, the cell cul-
ture supernatant was collected for the analysis of the
collagen I protein synthesis, and the RNA was isolated
to analyze the gene expression.
Analysis of cell proliferation
An alamarBlue assay was used to indirectly measure
cell proliferation by using the reducing power of viable
cells. The medium was removed from the cells and
700 μl of a 10% alamarBlue solution in a medium with
10% FCS was applied to the cells and they were then in-
cubated for 3 h at 37 °C. Subsequently, each well was
analyzed in duplicate using spectrophotometry at 570
nm versus 595 nm against the blank (10% alamarBlue
solution incubated without cells).
Analysis of the collagen I protein synthesis
The collagen I protein synthesis was measured from
day-5 cryo-preserved cell culture supernatants after
PRP stimulation with the MicroVue C1CP EIA kit
(TECOmedical, Germany). The collagen I protein syn-
thesis was normalized to the cell proliferation on day 5.
Analysis of gene expression
RNA was isolated from the cells on day 5 directly in the
well using the NucleoSpin RNA II Kit (Machary Nagel,
Germany) according to the manufacturer’s instructions.
Cells in triplicate/6 repeats (negative control) from each
donor were pooled. RNA quantity and purity were ana-
lyzed with a Nanodrop ND-1000 spectrophotometer
(PeqLab Biotechnologie, Germany). A total of 100 ng of
RNA was transcribed into complementary DNA (cDNA)
using the qScript cDNA Supermix (Quanta BioSciences,
USA) with the Epgradient Mastercycler (Eppendorf,
Germany). For the quantitative real-time PCR (qRT-
PCR) analysis, 1.25 ng of cDNA was used as the PCR
template. A total of 20 μl of Sybr Green mastermix was
used for each well and consisted of: 12.5 ml of Sybr
Green Supermix (Quanta BioSciences), 6.5 μl of RNase/
DNase-free water, and 1 μl of a primer mix (10 μM). All
the primer sequences were designed using the Primer 3
software (Freeware; http://frodo.wi.mit.edu/primer3),
and were produced by Tib Molbiol, Berlin, Germany
(Table 1). A qRT-PCR program with an initial denatur-
ation step for 3 min at 94 °C was used, followed by an
amplification program with 40 repeated cycles (95 °C
for 15 s, amplification temperature for 45 s, 72 °C for
30 s), and a melting curve program. The results were
analyzed with the Realplex Software (Eppendorf ). The
relative gene expression levels were normalized to
GAPDH and calculated using the 2-ΔCt method.
Growth factor quantification from the PRP
Growth factors such as PDGF-AB, IGF-I, TGF-β1,
BMP-7, and BMP-12 (also known as growth and
Fig. 1 Synopsis of the experimental set up
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differentiation factor-7, GDF-7) were analyzed using
ELISA according to the manufacturer’s instructions.
The PRP was thawed and clotted for about 30 min at
room temperature and centrifuged at 1000 × g for 10
min before being used for the ELISA analysis. The de-
tails for the ELISA kits are set out in Table 2. The
growth factor concentration was normalized to the total
protein content of the PRP, which was analyzed by a
Coomassie Plus Protein Assay (Thermo Fisher Scien-
tific, Germany).
Statistics
A statistical analysis was performed for 4 individual
groups (n = 6) using the Mann-Whitney-U Test. The
P-value was set to p ≤ 0.05 and adjusted using the
Bonferroni Holm correction. A Spearman’s Rho cor-




The exemplary characterization of 8 hTLC cultures revealed
high amounts of collagen I (2-ΔCt = 2.38 ± 0.85) and an
abundance of the tendon markers scleraxis (2-ΔCt = 0.003 ±
0.002) and Mohawk homeobox (2-ΔCt = 0.015 ± 0.006) in ac-
cordance with previous studies [41]. Osteocalcin expression
was weak in all the cells (2-ΔCt = 0.0006 ± 0.0002), while col-
lagen II was only present in 5 of the 8 hTLC cultures at a
negligible level (2-ΔCt = 0.00001 ± 0.00001).
Platelet and growth factor quantification in the PRP
The platelet concentrations showed no significant dif-
ferences between the 4 investigated donor groups. The
median of the platelets was 3.6 × 108 platelets/ml for
the younger male group and 4.5 × 108 platelets/ml for
the 3 other groups (Fig. 2a).
The growth factor quantification revealed no signifi-
cant differences between the groups. IGF-1 had the
highest concentrations in the PRP, followed by TGF-β1
and PDGF-AB (Fig. 2b). Only 1 of the 24 PRPs con-
tained a very low amount of BMP-7 (0.0004 pg/μg),
while low levels of BMP-12 (0.021 pg/μg) were detected
in 1 other sample. The PDGF-AB concentrations
significantly correlated with the platelet concentrations
in the PRP (rs = 0.469, p = 0.037). The correlation be-
tween the TGF-β1 and PDGF-AB concentrations was
also significant (rs = 0.877, p < 0.001).
Cell proliferation
Cell proliferation was significantly increased in all the
groups by stimulation with PRP compared to the posi-
tive (10% FCS, p ≤ 0.048) and negative controls (2%
FCS, p ≤ 0.0001). Significantly increased cell prolifera-
tion was further observed for all the hTLCs of the
positive compared to the negative control group
(p ≤ 0.0001). Additionally, in the group with the
males over 65 years of age, the PRP showed significantly
reduced stimulation potential compared to the group with
the males under 65 years of age (p = 0.009). The cell prolif-
eration did not correlate with the platelet or the growth
factor concentrations of the PRP (Fig. 3).
Collagen I protein synthesis
In all the analyzed groups, the absolute collagen I syn-
thesis (without normalization to cell proliferation) was
significantly increased in the PRP-stimulated cells and
the positive control group (10% FCS) compared to the
negative control group (2% FCS, p ≤ 0.005), but not
between the positive control (10% FCS) and the
PRP-treated cells. In addition, the PRP stimulation of the
female donors (>/< 65 years) resulted in a significantly
higher increase in total collagen I synthesis compared to
the respective male groups (< 65 years: p = 0.043, > 65
years: p = 0.002) (Fig. 4a).
With normalization to cell proliferation, the relative
collagen I synthesis was significantly reduced in the
PRP-treated cells compared to the hTLCs of the posi-
tive (10% FCS, p ≤ 0.01) and negative controls (2% FCS,
p ≤ 0.0001), as well as in the positive compared to the
negative control (p ≤ 0.03). In the younger male group,
the PRP stimulation led to significantly reduced colla-
gen I synthesis compared to the older male (p = 0.003)
and the younger female groups (p = 0.006) (Fig. 4b).
Correlation analysis revealed a significant negative cor-
relation between the PDGF-AB concentration and the
relative collagen I synthesis (rs = − 0.502, p = 0.017).
Gene expression
Collagen I expression was significantly reduced after
PRP treatment compared to the positive control in the
younger male (p = 0.016) and older female (p = 0.016)
groups. Additionally, in the hTLCs of the female donors
over the age of 65, the collagen I expression in the posi-
tive control was significantly increased compared to the
negative control (p = 0.005). In the younger female
group, the collagen I expression was significantly re-








Primer sequence [5′ – 3′]
GAPDH NM_002046 115 Forward: CCACTCCTCCACCTTTGACG
Reverse: CATGAGGTCCACCACCCTGT
Col-I NM_000088 197 Forward: TGACCTCAAGATGTGCCACT
Reverse: ACCAGACATGCCTCTTGTCC
Col-III NM_000090 199 Forward: GCTGGCATCAAAGGACATCG
Reverse: TGTTACCTCGAGGCCCTGGT
Osteocalcin NM_199173 209 Forward: CCCAGGCGCTACCTGTATCAA
Reverse: CTGGAGAGGAGCAGAACTGG
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controls (p = 0.009). No significant differences were de-
tected in the older male group (Fig. 5a).
The collagen III expression showed significant eleva-
tion in the male group under the age of 65 compared to
the negative (p = 0.002) and positive controls (p = 0.004).
In the hTLCs of the female donors under 65, the colla-
gen III expression was induced in the PRP-treated cells
compared to the positive control (p = 0.016), but it was
significantly lower in the positive compared to the nega-
tive control (p = 0.005). In the cells of the older female
donors, the collagen III expression was significantly in-
creased in the PRP compared to the negative control
(p = 0.007). No significant differences were observed
for the older male group (Fig. 5b).
The osteocalcin expression was unaffected by the PRP
or FCS treatment of the hTLCs (Fig. 5c).
No correlations were detected between the growth factor
content in the PRP and the gene expression of the hTLCs.
Discussion
The current study for the first time describes the
stimulating effects of autologous PRP on the same pa-
tients tenocytes of the human rotator cuff. We hereby
assessed parameters such as tenocyte proliferation as
well as expression and synthesis of extracellular matrix
components, particularly collagen I and III. were sig-
nificantly improved (without normalization to cell pro-
liferation). As discussed later, this finding is in general
accordance with other in vitro studies in the field that
describe enhanced cell proliferation, tendon matrix syn-
thesis, and gene expression under allogenic PRP of dif-
ferent configurations [13, 17, 22, 24, 46].
The effect of PRP was investigated in hTLCs of fe-
male and male subgroups of patients who were under
and above 65 years of age. Some clinical cohort studies
had suggested that a higher patient age is related to un-
successful RC repair, but no consistent age limits have
been defined [3, 11, 14, 19, 35, 37, 53, 61]. Furthermore,
a sex-related effect had been advocated by some
authors [10, 19], while others could not confirm this
observation [35, 38, 54, 61].
If patient age or sex was a critical issue, standard RC
repairs would be unsatisfactory in those beyond certain
limits, possibly demanding additional biological RC re-
pair augmentation, for example with growth factors ob-
tained with PRP [1, 23, 24, 31, 40, 45, 49].
If, for instance, elderly female patients required add-
itional biologic augmentation, autologous PRP might be
one possible approach, as suggested in the present study.
Recent in vitro studies have described age-related differ-
ences in biologic RC cell potential among male and fe-
male patients, with a weaker potential in those above the
age of 65 [27, 28]. Tenocyte-like cells can be stimulated
with growth factors such as BMP-2 and -7 by means of
Table 2 ELISA Kits
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Fig. 2 a Platelet and b growth factor concentrations in the PRP of the four investigated donor groups. No significant differences were found between
the groups. Stars and circles mark the outliers
Pauly et al. BMC Musculoskeletal Disorders          (2018) 19:422 Page 5 of 10
increased cell activity and collagen I synthesis in eld-
erly male and female patients [27, 28]. As discussed
later, BMP-7 could not be quantified in the PRP prep-
aration approach currently employed. However, the
blend of other autologous growth factors herein dem-
onstrated stimulating effects, suggesting that PRP
might have potential when it comes to augmentation,
particularly in this RC repair patient cohort with a pos-
sible biological demand.
Several methodological features of the present re-
search differ from existing in vitro studies on PRP and
tendon cells and provide new insights. A major strength
of this study is that it is the first approach to investigate
the effect of PRP on supraspinatus tenocytes of the
same patient, representing the clinical and intraopera-
tive application of autologous PRP. This approach
requires a more elaborate protocol to allow for intraop-
erative tendon harvest, subsequent cell isolation, and
Fig. 3 Cell proliferation after PRP stimulation in the four investigated donor groups normalized to the negative control. The PRP led to significantly
increased cell proliferation compared to the positive and negative controls. Additionally, the positive control showed an elevated cell proliferation
compared to the negative control. Cell proliferation in the PRP-treated cells was significantly reduced in the older compared to the younger
male groupStars indicate significant differences between the groups (p≤ 0.05)
Fig. 4 Total and relative collagen I synthesis normalized to the negative control. a The total collagen I synthesis was significantly increased in the
PRP group and the positive control compared to the negative control. PRP treatment led to significantly elevated effects in the hTLCs of the older
compared to the younger donors. b Collagen I synthesis relative to cell proliferation was significantly reduced in the PRP group compared to
the positive and negative controls, as well as in the positive compared to the negative control. In the younger male donors, the relative
collagen I synthesis was significantly reduced compared to the older male and younger female groups. Stars indicate significant differences at
p ≤ 0.05 between groups
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timed cell cultivation prior to scheduling patients for
blood samples, PRP preparation, and application.
Furthermore, the present study features the largest
number of enrolled donor patients of either sex or age
group, and thus represents the typical patient cohort
undergoing RC repair. Other studies in the field have
assessed only monadic numbers of donors with allo-
genic PRP preparations [13, 17, 22, 24, 46]. Cross et al.
involved n = 20 RC samples, but these received allo-
genic PRP preparations and had irreparable and
long-standing RC tears (cuff tear arthropathy), which
does not represent the patient cohort undergoing RC re-
pair (in contrast to the donors in the present study) [12].
Another strength of this study is that tissue samples
were obtained from torn rotator cuffs at the site of re-
pair (in contrast to intact rotator cuff material [55]).
This may provide more specific insight into the bio-
logical effect of PRP on the targeted type of rotator cuff
tissues when compared to tendon cultures with other
origins [12]. In this regard, de Mos et al. suggested that
tenocytes from degenerated and torn RCs might re-
spond differently to PRP than the intact hamstring ten-
don cells of the young individuals investigated in their
study [13]. However, their observation of increased
tenocyte proliferation is in accordance with our present
findings. The authors furthermore suggested a possible
decrease of collagen synthesis per cell which is con-
firmed in our results, where total collagen I protein
synthesis was increased but relative synthesis (normal-
ized to cell proliferation) was significantly reduced.
Could this be one reason why current clinical studies
with this regard are rather disencouraging? With re-
spect to the increased cell proliferation we believe it is
more precise to differentiate between total and relative
collagen I synthesis, even though it remains a gap of
knowledge which of these parameters is the most rele-
vant for successful clinical transfer. In addition, de Mos
et al. observed reduced gene expression of collagen I,
which again is in accordance with the present findings
in torn RC tenocytes. The authors also described upreg-
ulation of matrix-degrading enzymes (matrix metallo-
proteinase – MMP - 1 and 3) in PRP-exposed cells, and
concluded that PRP might accelerate the catabolic de-
marcation of traumatically injured tendon matrices
[13]. We cannot compare these results to degenerative,
torn RC tissue, as MMP expression was not assessed in
the present study. However, Cross et al. described re-
duced matrix degradation and inflammation cytokines
in elderly, torn RC-tenocytes treated with the same
leukocyte-poor PRP preparation set as in the present
study (Arthrex ACP®).
In the current research, tendon cell characterization
was conducted prior to studying the cell response. This
should be considered important enough to exclude the
analysis of unspecific fibroblast cultures [41], and was
conducted by some authors assessing the effect of PRP on
tendon cells after characterization for tendon-specific
markers such as scleraxis or decorin [17, 24]. In rodent
tendon stem cells, PRP induced tenocyte differentiation,
while adipocyte, chondrocyte, and osteocyte lineages were
suppressed [8]. This reflects the present findings in human
tenocytes, namely that osteocalcin expression was un-
affected by PRP application.
A weakness of the present study is that no different PRP
dosages were assessed, as other authors in this field have
described previously [13, 17, 46]. The dose-dependent re-
sponse of tenocytes to applied growth factors has, how-
ever, been reported elsewhere [40, 62].
Fig. 5 Relative gene expression measured by qRT-PCR and normalized to GAPDH and the negative control (line). Stars above brackets mark
significant differences between these groups at p≤ 0.05. Stars alone mark significant differences to the negative control. a Collagen I expression
was significantly reduced in all the investigated groups except the older male group compared to the positive control. b The expression of
collagen III was significantly increased in the PRP-treated cells compared to the positive and/or negative control in all the groups except the
older males. c No significant differences were demonstrated for the osteocalcin expression
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Growth factors (such as BMP 2 and 7) have been
found to stimulate human RC cells, but dosages beyond
the ideal concentration reduced tendon cell prolifera-
tion and collagen production [40]. Sadoghi et al. found
a significant effect of PRP on RC fibroblast proliferation
in vitro, with an optimal benefit using a onefold or
5-fold, but not 10-fold, PRP concentration [46]. Further
studies have demonstrated that increasing platelet con-
centrations in PRP applications beyond an ideal level
does not result in further anabolic upregulation (in ani-
mal/human tenocytes) [4, 17]. In contrast, (too) high
concentrations have been shown to have inhibitory ef-
fects on proliferation and collagen production, while
MMP production increased, which is possibly counter-
productive when it comes to tendon bone regeneration
[4, 17]. It has been suggested that an over-stimulation
of cells might result in adverse effects, such as
poorly-differentiated scar tissue at the insertion site [6,
57]. Accordingly, the chosen PRP concentration in the
present study may not have been optimal, as the rela-
tive collagen I synthesis was significantly reduced
(when normalized to cell proliferation). Moreover, an
increase in PDGF-AB concentration in the PRP was
found to correlate with a reduced relative collagen I
synthesis, indicating that lower PRP concentrations
could be beneficial. However, even if the optimal PRP
dosage in vitro is known, it nevertheless remains chal-
lenging to transfer this knowledge to the clinical set-
ting. It is technically difficult to influence or optimize
growth factor dosages in the final PRP product intraop-
eratively, as this correlates to plasma viscosity and con-
centration at the time of venous blood sampling.
As the stimulation of osteoblasts is helpful for
re-establishing the tendon-bone footprint following RC re-
pair, growth factors with bone and tendon-stimulating po-
tential (such as BMP-7 [26, 27, 40, 56, 62] and − 12 [29,
49, 59]) might be beneficial at the repair site. Accordingly,
the current study aimed to quantify the amount of these
factors to gain further insight, but the quantities were
below the technical detection limit except for 1 donor
with a low but detectable level of BMP-7 and 1 donor with
a low level of BMP-12. This could either be a technical
issue related to insufficient sensitivity of the kits or the
fact that these respective growth factors are indeed absent
in the PRP preparations.
To date, more clinical and radiographic studies on
PRP and RC repairs have been published than in vitro
studies on the biological characteristics of available PRP
products. Some studies suggested a pain reduction fol-
lowing PRP application [16, 44]. However, recent re-
views and meta-analyses found no significant effects of
PRP augmentation in the treatment of full thickness RC
tear repairs by means of outcome scores or re-tear rates
[5, 7, 21, 30, 47, 51, 60, 63].
The question arises as to why the majority of clinical and
radiographic studies on PRP augmentation in RC repair do
not confirm the promising in vitro studies that generally
describe positive effects of PRP on RC tendon cells.
One issue is the growth factor dose-dependent re-
sponse of tendon cells and the difficulty of affecting their
concentration in clinical practice, as discussed above.
Yet other factors may also account for this controversy.
Any analysis of the literature is complicated by the lack
of standardization of study protocols, PRP preparation
techniques, and the respective outcome measures in
clinical studies [51].
There is a broad range of PRP preparations distributed
in the market and employed in several studies. Yet it is
not just the content and concentrations of platelets, white
blood cells, and growth factors that differ significantly be-
tween different products and methods (1- versus double
spin process), but also intra-individual variations of PRP
products [12, 32, 34]. This variation may contribute to
inhomogenous results, as may further variables in clinical
studies such as the application time (intraoperatively/days
later) and site (underneath the reconstructed tendon-bone
unit or over the top) [60]. Finally, the actual surgical re-
construction technique (single vs. double row repair) and
postoperative rehab protocols may further account for dif-
ferences and hinder comparability.
These variables might contribute to the understand-
ing of heterogeneous results in clinical and radio-
graphic studies and the demand for further
translational studies, while PRP generally shows effects
on human RC tendon cells in vitro.
Conclusions
In this study, autologous PRP was a source of growth
factors such as IGF-1, TGF-β, and PDGF-AB, but no
detectable amounts of BMP-7 and -12 were found. PRP
had an anabolic effect on the human rotator cuff teno-
cytes of the same individual in vitro by means of in-
creased cell proliferation. On the other hand, and
absolute, but nor relative collagen I synthesis and gene
expression was significantly reduced and might explain
limited clinical results of PRP applications. These re-
sults encourage further studies on clinical outcomes
with more comparable standards in terms of prepar-
ation and application methods.
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